U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07358182) titled 'Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer' on Jan. 14.
Brief Summary: This study is a multicenter, observational, real-world investigation. The research plans to enroll 300 HER2-positive and HER2-low breast cancer patients who meet the inclusion criteria. All patients included in the analysis are currently receiving or are scheduled to receive a treatment regimen containing Trastuzumab-rezetecan. There are no restrictions on the treatment regimen, which is entirely based on the clinician's choice. The study aims to evaluate the efficacy and safety of the treatment regimen containing Trastuzumab-re...